Computational immunogenomic approaches to predict response to cancer immunotherapies
Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …
establishment of large-scale genomic collaborative efforts along with the development of …
Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and …
The past decade has witnessed a revolution in cancer treatment by the shift from
conventional drugs (chemotherapies) towards targeted molecular therapies and immune …
conventional drugs (chemotherapies) towards targeted molecular therapies and immune …
Five-year clinical outcomes after neoadjuvant nivolumab in resectable non–small cell lung cancer
S Rosner, JE Reuss, M Zahurak, J Zhang, Z Zeng… - Clinical Cancer …, 2023 - AACR
Abstract Purpose: Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–
small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant …
small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant …
Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy
C Aggarwal, R Ben-Shachar, Y Gao… - JAMA network …, 2023 - jamanetwork.com
Importance There are few studies assessing the association of tumor mutational burden
(TMB) and clinical outcomes in a large cohort of patients with diverse advanced cancers …
(TMB) and clinical outcomes in a large cohort of patients with diverse advanced cancers …
[HTML][HTML] Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a
standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and …
standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and …
[HTML][HTML] Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC
Introduction Although programmed cell death protein 1 and programmed death-ligand 1 (PD-
L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay of …
L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay of …
[HTML][HTML] Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non–small cell lung cancer
B Pellini, RW Madison, MA Childress, ST Miller… - Clinical Cancer …, 2023 - AACR
Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced
driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after …
driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after …
[HTML][HTML] Tumor heterogeneity: preclinical models, emerging technologies, and future applications
Heterogeneity describes the differences among cancer cells within and between tumors. It
refers to cancer cells describing variations in morphology, transcriptional profiles …
refers to cancer cells describing variations in morphology, transcriptional profiles …
[HTML][HTML] Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer
Understanding the role of the tumor microenvironment (TME) in lung cancer is critical to
improving patient outcomes. We identified four histology-independent archetype TMEs in …
improving patient outcomes. We identified four histology-independent archetype TMEs in …
[HTML][HTML] Emerging biomarkers and the changing landscape of small cell lung cancer
A Keogh, S Finn, T Radonic - Cancers, 2022 - mdpi.com
Simple Summary Small cell lung cancer (SCLC) is an aggressive cancer representing 15%
of all lung cancers. Unlike other types of lung cancer, treatments for SCLC have changed …
of all lung cancers. Unlike other types of lung cancer, treatments for SCLC have changed …